Group 1 - The Beijing Stock Exchange and Shanghai Stock Exchange will hold meetings on November 21 to review four IPO applications, all of which have been approved [1] - Aide Technology focuses on orthopedic medical devices, including spinal, trauma, and sports medicine products, aiming to become a leading provider in the domestic market [2] - The company has developed multiple core technologies and holds 110 patents, including 45 invention patents, and has received various recognitions as a high-tech enterprise [2][9] Group 2 - The IPO will be sponsored by Debon Securities, with a total share capital of approximately 88.59 million shares, planning to issue up to 29.53 million shares [3] - The major shareholders are Lu Qiang and Huang Meiyu, who together control 79.07% of the company [4] - The company aims to raise 197 million yuan for three major projects, including orthopedic consumables expansion and R&D center construction [6] Group 3 - Financial data shows total assets of approximately 652 million yuan as of June 30, 2025, with a net profit of about 38.22 million yuan for the first half of 2025 [5] - The company has maintained a low debt ratio, with a debt-to-asset ratio of 13.07% as of June 30, 2025 [5] - The company has a strong revenue stream, with reported revenues of 149 million yuan for the first half of 2025 [5] Group 4 - The company has a comprehensive product matrix covering all areas of orthopedics, including spinal, trauma, joint, and sports medicine [8] - Aide Technology emphasizes providing affordable and high-quality orthopedic products, focusing on grassroots medical markets [9] - The company has established a strong brand presence in the minimally invasive spinal treatment sector [9]